Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(11;19)(q23;p13) KMT2A/MYOF1

Written2018-01Jean-Loup Huret, Philippe Dessen

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 1406

Clinics and Pathology

Disease -

Genes involved and Proteins

Gene NameKMT2A
Location 11q23.3
Gene Name

To be noted

Non-annotated chromosomal abnormality. Preliminary data : if you are an author who wish to write a full paper/card on the chromosome abnormality, go to  How to contribute

Bibliography

The t(11;19)(q23;p13) fusing MLL with MYO1F is recurrent in infant acute myeloid leukemias
Duhoux FP, Ameye G, Libouton JM, Bahloula K, Iossifidis S, Chantrain CF, Demoulin JB, Poirel HA
Leuk Res 2011 Sep;35(9):e171-2
PMID 21620472
 
The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22
Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y, Yuza Y, Eto Y, Hayashi Y
Oncogene 2005 Aug 4;24(33):5191-7
PMID 15897884
 


Translocations implicated (Data extracted from papers in the Atlas)

 t(11;19)(q23;p13) KMT2A/MYOF1

External links

KMT2A (11q23.3) MYOF1 ()

Mitelman databaset(11;19)(q23;p13) [Case List]    t(11;19)(q23;p13) [Transloc-MCList] KMT2A/MYOF1 [Fusion-MCList]
COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMap (UZH-SIB Zurich)[select an item]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jan 10 17:22:41 CET 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.